HC Wainwright Reaffirms Buy Rating for Aprea Therapeutics (NASDAQ:APRE)

Aprea Therapeutics (NASDAQ:APRE)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $20.00 target price on the stock.

Aprea Therapeutics Price Performance

NASDAQ APRE opened at $3.08 on Tuesday. The company’s fifty day moving average is $3.45 and its two-hundred day moving average is $3.56. Aprea Therapeutics has a 52-week low of $2.15 and a 52-week high of $8.85. The firm has a market capitalization of $16.74 million, a price-to-earnings ratio of -1.10 and a beta of 0.88.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.11. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. The firm had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.45 million. As a group, sell-side analysts expect that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Aprea Therapeutics news, Director Marc Duey sold 6,462 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $4.58, for a total value of $29,595.96. Following the completion of the transaction, the director now directly owns 233,651 shares of the company’s stock, valued at approximately $1,070,121.58. The trade was a 2.69 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Bernd R. Seizinger acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, October 11th. The stock was bought at an average price of $2.68 per share, with a total value of $26,800.00. Following the transaction, the director now directly owns 44,730 shares in the company, valued at $119,876.40. The trade was a 28.79 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 42,290 shares of company stock valued at $165,096. 12.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP acquired a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned about 0.20% of Aprea Therapeutics at the end of the most recent reporting period. 34.19% of the stock is currently owned by institutional investors.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.